Constipation Clinical Trial
Official title:
Comparison of Taste and Texture of Metamucil, Volcolon and Psyllium Orange Generic
The purpose of this study is to compare 1. taste and 2. texture/palatability of Metamucil orange®, Volcolon® and generic orange psyllium.
Background of the study:
A pleasant taste of a prescription improves patient compliance and adherence. According to
the literature, only 50% of patients who suffer from chronic diseases adhere to treatment
recommendations (1). This results in suboptimal outcomes (2). There are numerous factors that
affect adherence, including characteristics of the illness, interaction between physician and
patient, the complexity and duration of treatment, side effects of treatment and costs of
treatment (3). Furthermore, medication palatability is also crucial for adherence. Several
studies have addressed the palatability of medication for different disorders, like
hypertension, HIV and Alzheimer's disease (4-6). Therefore, pharmaceutical companies pay
attention to manufacture more formulations and add pleasant flavours which may improve the
palatability. Fiber supplements are increasingly used for treatment of chronic constipation
both in adults and children. In the Netherlands several formulas are available such as
Metamucil orange®, Volcolon® en generic psyllium orange. These are effective and save
formulas. Little literature is available concerning taste and laxatives or fibers, although
many patients complain about taste and texture of the preparations. Studies with polyethylene
glycol preparations performed by our research group demonstrated some differences in
palatability between these preparations (7-9). There are hardly any studies about fibers and
taste. The taste is mentioned to be acceptable; one study compares dried prunes with psyllium
and concludes there is no difference in taste experience (10). In order to improve patient
compliance, it is of clinical importance to know which preparations are the most acceptable
to the patient, and use that as first choice. We hypothese that the taste and palatability of
Metamucil orange® is preferable.
Objective of the study:
Comparison of 1. taste and 2. texture/palatability of Metamucil orange®, Volcolon® and
generic orange psyllium.
Study design:
It is a double blind, randomized, crossover study.
Study population:
100 healthy volunteers (primary recruitment of medical students).
Intervention: All healthy volunteers will try the 3 different formulas. After swallowing the
first formula, the mouth will be rinsed with water. Then the second formula will be tried,
after rinsing the mouth again the third formula will be tried. Every time after tasting a
formula, the questionnaire is filled in, before starting with the next formula. The maximum
intake is 3 x 25 ml (75 ml), this is 37,5% of one dosage advised quantity of fibre. The
sequence in which the formulas are tasted is randomized.
Preparations and dosage
Each sachet needs to be solved in a glass of water. This matches (approximately) 200 ml.
During the study the volunteers will taste 3 x 25 ml of water. This matches 37,5% of one
dosage. The average intake of psyllium fibers is 1-3 sachets a day. Dosage if the different
products:
- Volcolon sugar free (Dutch name: Volcolcolon suikervrij): 1 sachet contains 4 g powder o
980mg/g psyllium fibers x 4 g per sachet = 3.92 g psyllium fibers/sachet o So 25 ml
contains 0.490 g psyllium fibers
- Metamucil Orange: 1 sachet contains 3.4 g psyllium fibers o So 25 ml contains 0.425 g
psyllium fibers
- Psyllium Orange: 1 sachet contains 3.25 g psyllium fibers o So 25 ml contains 0.406 g
psyllium fibers These three products are the most used products for each brand
(Metamucil orange, Volcolon and generic orange). This leads to the greatest coverage of
the three brands in the Netherlands. The volunteers will swallow 25 ml of each product,
three in total. This leads to an intake of 1.32 g (0.490 g + 0.425 g + 0.406= 1.32 g)
psyllium fibers.
According to the Dutch Board of Health (in Dutch: Gezondheidsraad) the average intake of
fibers should be between 30 and 40 g a day. So, the volunteers will swallow approximately 4%
(3.3 - 4.4%) of the advised intake of fibers. Therefore, we do not expect any problems when
the volunteers swallow these products.
Nature and extent of the burden and risks associated with participation, benefit and group
relatedness (if applicable): The maximum intake is 3 x 25 ml (75 ml), this is 37,5% of one
dosage advised quantity of fibre. Therefore, we do not expect any problems when the
volunteers swallow these products.
References:
1. World Health Organisation. Adherence to long term therapies: evidence for action. 2003.
2. Osterberg L, Blaschke T. Adherence to medication 1. N Engl J Med 2005 August
4;353(5):487-97.
3. Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic
treatment: a review of literature 1. J Behav Med 2008 June;31(3):213-24.
4. Van der Linden D, Callens S, Brichard B, Colebunders R. Pediatric HIV: new opportunities
to treat children 1. Expert Opin Pharmacother 2009 August;10(11):1783-91.
5. Meier CM, Simonetti GD, Ghiglia S, Fossali E, Salice P, Limoni C et al. Palatability of
angiotensin II antagonists among nephropathic children 1. Br J Clin Pharmacol 2007
May;63(5):628-31.
6. Yan YD, Woo JS, Kang JH, Yong CS, Choi HG. Preparation and evaluation of taste-masked
donepezil hydrochloride orally disintegrating tablets 1. Biol Pharm Bull
2010;33(8):1364-70.
7. Felt-Bersma R.J., Kooyman G., Kuipers E.J. Colonic lavage prior to colonoscopy:
comparable outcomes of two polyethylene-glycol preparations and a sodium-phosphate
solution. Ned Tijdschr Geneeskd. 2004 Jan 24; 148 (4): 181-5
8. Szojda MM, Mulder CJ, Felt-Bersma RJ. Differences in taste between two polyethylene
glycol preparations.J Gastrointestin Liver Dis. 2007;16(4):379-81
9. Lam TJ, Mulder CJ, Felt-Bersma RJ. Differences in taste between three polyethylene
glycol preparations: a randomized double-blind study. Patient Prefer Adherence.
2011;5:423-6.
10. Yan YD, Woo JS, Kang JH, Yong CS, Choi HG. Preparation and evaluation of taste-masked
donepezil hydrochloride orally disintegrating tablets 1. Biol Pharm Bull
2010;33(8):1364-70.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Recruiting |
NCT06292949 -
Clinical Study of Resistant Starch in Improving Constipation
|
N/A | |
Recruiting |
NCT04132661 -
MRI Assessment of Mode of Action of Bisacodyl, Single Dose
|
Phase 4 | |
Completed |
NCT02726295 -
The Efficacy of Mutaflor(E. Coli Nissle 1917, Mutaflor®) for Chronic Constipation:Multicenter Study
|
Phase 4 | |
Terminated |
NCT02839889 -
Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)
|
Phase 4 | |
Recruiting |
NCT02255747 -
Anal Dilatation for Infants and Children With Constipation
|
N/A | |
Completed |
NCT02246647 -
Biomarkers for Intestinal Permeability in Patients With Constipation
|
||
Completed |
NCT01566409 -
Maintenance Treatment for Children With Constipation
|
N/A | |
Completed |
NCT01695915 -
Diurnal Variation in Rectal Diameter
|
N/A | |
Completed |
NCT01710579 -
Normal Values in Ano-rectal 3D High Resolution Manometry
|
N/A | |
Completed |
NCT02658201 -
Ultrafast MRI Imaging to Exclude Constipation
|
N/A | |
Completed |
NCT02863848 -
Effect of Inulin-type Fructans on Constipated Children.
|
N/A | |
Completed |
NCT01474499 -
A Trial of Docusate Sodium and Sorbitol Rectal Solution for the in Patients With Constipation
|
Phase 3 | |
Completed |
NCT01411501 -
Efficacy and Safety of Acupuncture for Functional Constipation
|
Phase 3 | |
Completed |
NCT01438567 -
A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy
|
Phase 3 | |
Completed |
NCT01170039 -
The Effectiveness of Lubiprostone in Constipated Diabetics
|
Phase 4 | |
Completed |
NCT00931853 -
Efficacy and Tolerability of Cassia Fistula Plus Senna Alexandrina Miller (Sugar Free) in the Chronic Functional Constipation (CFC).
|
Phase 3 | |
Active, not recruiting |
NCT02442115 -
Impact of Improving GI Symptoms on Autism Symptoms and Oxidative Stress
|
||
Completed |
NCT00994851 -
Evaluation of Cassia Fistula + Senna Alexandrina Miller in the Chronic Functional Constipation Treatment.
|
Phase 3 | |
Terminated |
NCT01003249 -
Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen
|
Phase 4 |